ReviewDrug, healthcare and patient safety2016
Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis.
Daniela Pugliese et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papertrialcites it